Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | USP1 | O94782 | 9/20 | 0.38 |
| ▸ | WDR48 | Q8TAF3 | 9/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337313 | 0.88 | ALDH1A1 (0.35) | USP1WDR48MAPTPDE10AAR | |
| SCHEMBL3336084 | 0.87 | CHRM4 (0.38) | CHRM4PDE10A | |
| SCHEMBL3337744 | 0.83 | CHRM4 (0.41) | CHRM4EIF4EBP1 | |
| SCHEMBL3340351 | 0.82 | PDE10A (0.40) | CHRM4PDE10A | |
| SCHEMBL3338808 | 0.81 | MAPT (0.36) | MAPTAR | |
| SCHEMBL3339867 | 0.79 | PDE10A (0.35) | PDE10AAREIF4EBP1 | |
| SCHEMBL3338195 | 0.77 | FABP3 (0.34) | MAPTEIF4EBP1 | |
| SCHEMBL14048760 | 0.77 | CHRM4 (0.41) | CHRM4MAPTPDE10A | |
| SCHEMBL3334994 | 0.76 | FABP3 (0.34) | USP1WDR48MEN1KMT2A | |
| SCHEMBL3337316 | 0.74 | GPBAR1 (0.34) | CHRM4AREIF4EBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422310-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150183800-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8952161-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140024665-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2014-01-23 | — | — | US | disclosed |
| US-8481738-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120122891-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8084614-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122891-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CHRM4 347/4885USP1 1837/4885WDR48 3111/4885 |
| US-20150183800-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CHRM4 347/4885USP1 1837/4885WDR48 3111/4885 |
| US-20140024665-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CHRM4 347/4885USP1 1837/4885WDR48 3111/4885 |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CHRM4 351/4885USP1 1843/4885WDR48 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.